+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Myoglobin, creatine-kinase-MB and cardiac Troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: Results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B



Myoglobin, creatine-kinase-MB and cardiac Troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: Results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B



Journal of the American College of Cardiology 34(3): 739-747



OBJECTIVES We examined the diagnostic performance of serum myoglobin, creatine-kinase-MB (CK-MB) and cardiac Troponin-I (cTnI) for predicting the infarct-related artery (IRA) patency in patients receiving TNK-tissue plasminogen activator (TNK-tPA) therapy for acute myocardial infarction (AMI) in the Thrombolysis in Myocardial Infarction (TIMI) 10B trial. BACKGROUND A reliable noninvasive serum marker of IRA patency is desired to permit early identification of patients with a patent IRA after thrombolysis. METHODS We measured myoglobin, CK-MB and cTnI concentrations in sera obtained just before thrombolysis (T0) and 60 min later (T60) in 442 patients given TNK-tPA and who underwent coronary angiography at 60 min. RESULTS Angiography at 60 min showed a patent IRA (TIMI flow grade 2, 3) in 344 and occluded IRA (TIMI flow grade 0, 1) in 98 patients. The median serum T60 concentration, the ratio of the T60 and T0 serum concentration (60-min ratio) and the slope of increase over 60 min for each serum marker were significantly higher in patients with patent arteries compared with patients with occluded arteries. The area under the receiver-operating characteristic (ROC) curve for diagnosis of occlusion was 0.71, 0.70 and 0.71 for the 60-min ratio of myoglobin, cTnI and CKMB, respectively. The 60-min ratios of gtoreq4.0 for myoglobin, gtoreq3.3 for CK-MB and gtoreq2.0 for cTnI yielded a probability of patency of 90%, 88% and 87%, respectively. CONCLUSIONS The diagnostic performance of serum myoglobin, CK-MB and cardiac Tropinin-I (cTnI) 60-min ratios was similar. The probability of a patent IRA was very high (90%) in patients with 60-min myoglobin ratio gtoreq4.0, and early invasive interventions to establish IRA patency may not be necessary in this group. Serum marker determinations at baseline and 60-min after thrombolysis may permit rapid triage of patients receiving thrombolytic therapy by ruling out IRA occlusion.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011033624

Download citation: RISBibTeXText

PMID: 10483955

DOI: 10.1016/s0735-1097(99)00274-0


Related references

Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: Results from TIMI 10A. American Heart Journal 134(4): 622-630, 1997

Serum myoglobin, cardiac troponin I and creatine kinase -MD, to assess reperfusion after thrombolysis for acute myocardial infarction Results from TIMI 10 B. Circulation 96(8 Suppl. ): I332, 10/21/97, 1997

Cardiac troponin I, CK-MB and myoglobin for early, noninvasive assessment of coronary reperfusion after thrombolysis for acute myocardial infarction Results from TIMI 10 A. Circulation 94(8 Suppl. ): I322, 1996

Multivariate associates of QT dispersion in patients with acute myocardial infarction: primacy of patency status of the infarct-related artery. TEAM-3 Investigators. Third trial of Thrombolysis with Eminase in Acute Myocardial Infarction. American Heart Journal 135(6 Pt 1): 1027-1035, 1998

ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. American Journal of Cardiology 85(3): 299-304, 2000

Global outcomes of ST-elevation myocardial infarction: comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial. American Heart Journal 154(1): 54-61, 2007

Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. Journal of the American College of Cardiology 19(1): 1-10, 1992

Acute ischemic heart disease - Global outcomes of ST-elevation myocardial infarction: Comparisons of the enoxaparin and thrombolysis reperfusion for acute myocardial infarction treatment-thrombolysis in myocardial infarction study 25 (ExTRACT-TIMI 25) registry and trial. American Heart Journal 154(1): 54-60, 2007

Non-invasive assessment of infarct-related artery patency after thrombolysis for acute myocardial infarction by ST resolution Results of the HIT-4 angiographic substudy. Journal of the American College of Cardiology 33(2 Suppl. A): 324A-325A, 1999

Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28. American Heart Journal 159(6): 964-971.E1, 2010

Cardiac markers in the early hours of acute myocardial infarction: clinical performance of creatine kinase, creatine kinase MB isoenzyme (activity and mass concentration), creatine kinase MM and MB subform ratios, myoglobin and cardiac troponin T. Scandinavian Journal of Clinical and Laboratory Investigation 56(8): 701-713, 1996

Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial. American Heart Journal 154(6): 1078-84 1084.E1, 2007

Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). American Heart Journal 149(2): 217-226, 2005

The combined use of pravastatin and thrombolysis in acute myocardial infarction Effect on the patency of infarct-related artery. European Heart Journal 20(ABSTR Suppl. ): 500, 1999

High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Circulation 101(23): 2690-2695, 2000